KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results.

D Fox, J Slim, E T Overton, A Doblado-Maldonado, P Jeffery, R A Grove, S D Advani, R Borsi, C M Parry, M Underwood, B Jones

HIV Med 27(7) 1189-1195

PMID41992416
PMCIDPMC13340934
DOI10.1111/hiv.70237
发表日期2026-04-17
入排依据:未发现恶性肿瘤人群证据。
已检查 1 张 PMC Figure,均未识别为 KM 图:FIGURE 1:ROC 图。
摘要

摘要

OBJECTIVES: As two-drug HIV-1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti-HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three- or four-drug regimens (3DRs/4DRs) among people with HIV-1 and isolated reactive anti-HBc. METHODS: Data were evaluated from GEMINI-1, GEMINI-2, STAT, TANGO and SALSA at various time points, including Weeks 48, 96, 144 and 196. Participants had hepatitis B virus (HBV) exposure, isolated reactive anti-HBc serology, no HBV infection and were naive to ART (GEMINI-1/-2, STAT) or virologically suppressed before switching (TANGO, SALSA). All studies except STAT had a 3DR/4DR comparator. RESULTS: Of 2798 participants, 76 (DTG/3TC, n = 44; 3DR/4DR, n = 32) had isolated reactive anti-HBc. Across studies, no instances of HBV reactivation occurred, and liver chemistry elevations were infrequent and generally mild. Among those naive to ART at baseline and receiving DTG/3TC, 78% (18/23) achieved HIV-1 RNA <50 copies/mL at Week 144 in GEMINI-1/-2, and 60% (3/5) achieved HIV-1 RNA <50 copies/mL at Week 48 in STAT. Among participants with virologic suppression at baseline who switched from 3DR/4DR to DTG/3TC, none experienced HIV-1 RNA ≥50 copies/mL at the end of TANGO (Week 196) or SALSA (Week 48). HIV-1 suppression rates were comparable to those of 3DRs/4DRs. CONCLUSIONS: This analysis provides new information about DTG/3TC treatment for people with HIV-1 and isolated reactive anti-HBc. There were high rates of HIV-1 suppression with DTG/3TC, no cases of HBV reactivation and no new safety signals identified.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1HIV‐1 virologic outcomes in participants with isolated reactive anti‐HBc who were (a) naive to ART at baseline or (b) virologically suppressed before switch to DTG/3TC. a In GEMINI‐1/‐2, 1 participant discontinued DTG + 3TC for non–efficacy‐related reasons by Week 48; by Week 96, three participants had discontinued DTG + 3TC for non–efficacy‐related reasons. b Data for HIV‐1 RNA <40 copies/mL and TND were not available for STAT. c Of the two participants in STAT with HIV‐1 RNA ≥50 copies/mL, one discontinued for non–efficacy‐related reasons (decision by physician; non‐compliance with study procedures) with HIV‐1 RNA ≥50 copies/mL and one had a change in ART that was not efficacy related (decision by participant or proxy due to incarceration). By Week 48, their HIV‐1 RNA measurements were <40 copies/mL. This post hoc analysis was completed using a Snapshot analysis; therefore, any changes in ART classified these participants as having HIV‐1 RNA ≥50 copies/mL, irrespective of the reason. d In TANGO, one participant discontinued DTG/3TC before Week 48 for non–efficacy‐related reasons. e In TANGO, one participant discontinued CAR before Week 144 for non–efficacy‐related reasons. ART, antiretroviral therapy; CAR, current antiretroviral regimen; c/mL, copies/mL; DTG, dolutegravir; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; TND, target not detected; W, week.
非 KM Figure